Evonik Refocuses Its Portfolio and German Sites, Funding Growth via Cost Cuts
Evonik Refocuses Its Portfolio and German Sites, Funding Growth via Cost Cuts
Evonik is sharpening its growth strategy through 2030 by giving every business a defined role, assigning specific profiles to its major German production sites, and directing investment toward higher-growth geographies and technologies. Financial room for those investments is being created by the Evonik Tailor Made efficiency programme, which will cut 3,200 jobs worldwide—about 2,150 of them in Germany—and further lower the group’s cost base. The plan was confirmed after a strategy meeting of the Executive Board and Supervisory Board and sits alongside ongoing divestments of C4 chemicals (Oxeno) and infrastructure (Syneqt) and the closure or consolidation of smaller German sites.
Portfolio Roles: Growth Drivers and Cash Generators
Businesses will be managed according to explicit role profiles. Some units are designated as growth drivers and will receive priority capital and resources; others are treated as cash generators expected to deliver stable returns and fund the rest of the portfolio. A new Designed Polymer Solutions line will combine activities with stronger growth potential in aerospace, automotive and gas separation, including applications linked to biogas and hydrogen. The aim is to stop spreading investment thinly across the entire portfolio and to concentrate expansion where Evonik sees structural demand and competitive advantage.
Clear Profiles for German Sites
Germany remains central to Evonik’s production footprint, but the company is defining a distinct role for each of its six major sites as a guide for future development and capital allocation. Implementation of these site profiles is beginning immediately. At the same time, smaller sites that lack long-term scale or strategic fit are being closed or consolidated. Hamburg and Bitterfeld are among the locations earmarked for closure, with activities transferred to larger plants. Precipitated-silica production from Rheinfelden and Düren is to be concentrated into a new large-scale facility in Marl, with the older plants scheduled to close later in the decade. The message is concentration: fewer, stronger sites rather than a dispersed network of subscale operations.
Tailor Made: Cost Cuts Create Investment Capacity
Evonik Tailor Made is the financial engine of the strategy. The programme’s first phase (2024–2026) is already delivering job reductions and savings; a second implementation phase will run from 2027 to 2029. In total, 3,200 positions will be eliminated worldwide, with the majority in Germany. Detailed measures are to be finalised by the end of 2026. Management has framed the cuts not as a standalone austerity exercise but as the means to free capital for growth projects and to improve the cost position of the remaining organisation in a structurally difficult European chemicals environment.
Targeted Growth Investments
Disodium Octaborate Tetrahydrate
With cost savings providing headroom, Evonik is launching growth projects in healthcare and biotechnology in Canada and Slovakia with a combined volume in the three-digit million-euro range. Further investment options in Asia and the Americas are under review. The stated goal is a more balanced regional revenue mix across Europe, Asia and the Americas, reducing over-reliance on the high-cost European base and capturing demand where markets are expanding faster.
Divestments and Portfolio Cleanup
The sales processes for the C4 chemicals business (Oxeno GmbH) and the infrastructure activities (Syneqt GmbH) are proceeding as planned. These divestments remove large, less-strategic blocks from the group and will, if completed, further simplify the portfolio and free management attention and capital. Withdrawal from activities judged to have insufficient long-term prospects is part of the same cleanup logic.
Context: Structural Pressure on German Chemicals
Evonik’s leadership has described the current environment as a structural and economic crisis for the industry. High energy costs, global overcapacity in some chains and intense competition have forced European specialty players to choose between incremental cost cutting and a more fundamental reshaping of portfolio and footprint. Evonik’s response combines both: deeper efficiency measures and a clearer hierarchy of businesses and sites, with growth capital reserved for selected technologies and regions.
Outlook
Evonik’s refocus of portfolio roles and German site profiles, funded by Tailor Made cost reductions, is a multi-year programme rather than a single announcement. Execution will be measured by the speed of job and cost reductions, the successful closure or sale of non-core assets, the ramp of designated growth projects, and whether the remaining core businesses deliver the margin and growth improvement the strategy assumes. For employees, customers and investors, the next milestones are the detailed site-by-site plans, progress on the Oxeno and Syneqt divestments, and evidence that savings are translating into sustainable investment capacity rather than one-off cuts.
Sources
Found this useful?
